Abstract:
To see if berberine is effective and safe in the treatment of prediabetes. Methods. On the treatment of T2DM, randomized studies of berberine against lifestyle change, placebo, and/or oral hypoglycemics intervention were included. Two reviewers independently retrieved study population characteristics and outcome outcomes. For the data that was available, meta-analyses were conducted. Results. This analysis includes 14 randomized trials with a total of 153 individuals. The quality of the methodology was often poor. The cointervention of berberine with lifestyle modification demonstrated a considerably hypoglycemic and anti-dyslipidemia effect when compared to lifestyle modification with or without placebo. Berberine did not exhibit a substantial improvement in glycemic control when compared to oral hypoglycemics such as metformin, glipizide, or rosiglitazone, although it did have a moderate antidyslipidemia benefit. In T2DM, hyperglycemia and dyslipidemia are common. However, because of the low methodological quality, small sample size, limited number of trials, and unknown bias concerns, the evidence for berberine in the treatment of T2DM should be regarded with caution. Patients with prediabetes who do not follow their treatment regimens are more likely to have negative results. Clinicians and health-care institutions are increasingly focused on improving drug adherence. We investigate the discrepancies in patient and provider perceptions of medication adherence obstacles in prediabetic patients.
Description:
This thesis submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy (B.Pharm) in East West University, Dhaka, Bangladesh.
